Annual Report and full year financial results
Starpharma released its annual report and financial results for the year ended 30 June 2016.
Financial Results
- Net cash burn (cash outflows before new capital) $17.5M
- Cash position at end of the year $46.0M
- Net proceeds of $32.6M from equity placement and share purchase plan
- Total revenue and other income $4.6M including the first US$2M DEP™ milestone from AstraZeneca
- Reported loss $22.7M
- Receipt of $3.4M R&D tax incentive
The Australian: Starpharma perks up on China condom deal
The Australian’s David Rogers reports that Starpharma has signed “an exclusive license and supply agreement with Shenyang SKY and Land Latex Co for the manufacture and sale of VivaGel condoms to the Government segment of the Chinese condom market”.
Starpharma initiates new DEP™ drug delivery program with AstraZeneca
Melbourne, Australia; 28 July 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the initiation a new DEP™ drug delivery program with AstraZeneca. The new agreement will see the application of Starpharma’s DEP™ platform to a further compound from AstraZeneca’s portfolio.
Starpharma signs license for a VivaGel® condom in China
Melbourne, Australia; 21 July 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the signing of an exclusive license and supply agreement with Shenyang Sky and Land Latex Co. Ltd. (Sky and Land) for the manufacture and sale of VivaGel® condoms to the Government segment of the Chinese condom market.
Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 June 2016.
Starpharma’s DEP™ eliminates cabazitaxel neutropenia
Melbourne, Australia; 25 May 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced that Starpharma’s DEP™ cabazitaxel eliminated neutropenia typical of cabazitaxel (Jevtana®) in a preclinical study.
The Conversation: Antiviral condoms will help protect Australian Olympians from STIs – here’s how
The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio.
Starpharma to present at ASX CEO Session
Starpharma is presenting today at The CEO Session Series event in Sydney.
Australian Olympic Team taking Dual Protect™ VivaGel® Condoms to Rio
Starpharma and Ansell today proudly announce that the Australian Olympic team will be provided with antiviral Dual Protect™ VivaGel® condoms for the upcoming Olympic Games in Rio de Janeiro.
VivaGel® active against Zika virus
Starpharma announced today that the VivaGel® active, astodrimer sodium (SPL7013), has been shown to have potent antiviral activity against the Zika virus in laboratory studies. The studies showed near complete antiviral protection at SPL7013 concentrations significantly below that used in the VivaGel® condom.